AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00526227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Secura ICD
Description: Secura Implantable Cardioverter Defibrillator (ICD) will be implanted
Study NCT01070199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: solid to liquid
Description: • This session will involve the same dense gelatin cubes previously described, but participants will be told that the solid cubes will turn to liquid when they come into contact with the acid in their stomach. This trial will be known as Solid to Liquid. A demonstration of the Solid to Solid and Solid to Liquid phases will be shown to the participant before they consume the load. Both phases exhibited by placing two cubes into separate containers filled with similar looking clear liquids. The Solid to Solid phase container will contain cold water so the cube stays in solid form. The Solid to Liquid phase container will contain hot water that will quickly dissolve the cube into a liquid form.
Study NCT02915133 — intervention group
Intervention type: PROCEDURE
Intervention: macular buckling surgery
Description: Participants with high myopia foveoschisis are scheduled to macular buckling (MB) surgery.
Study NCT01070199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: solid to solid
Description: Participants will be presented with dense gelatin cubes. These 1 x 1 x 1 cubes will have a solid appearance and require mastication, but is isocaloric to the beverage. However, after mastication and gastric processing, the solid rapidly breaks down into a clear fluid.However, participants will be informed that the cubes will remain the same solid consistency in their stomach. The masticatory process and stimulus form will be standardized through the use of a metronome. Participants will be required to chew the solid cube at a fixed rate prior to swallowing. Thus, adding to the cognitive impression that they are eating a solid when essentially the GI challenge will be similar to the beverage.
Study NCT02838186 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: retroflexion
Description: examination of the right colon with scope retroflexion
Study NCT02838186 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: forward view
Description: examination of the right colon in forward view
Study NCT02486263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Arm - acid suppression plus feeding bundle
Description: * Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)~* Total fluid volume restriction (120-140 milliliters/kilogram/day)~* Feeding duration over 30 minutes~* Infant feeds with right side down~* Infant is placed on back following feeds
Study NCT02486263 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional arm - acid suppression only
Description: -Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)
Study NCT03163277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine, darunavir/cobicistat, maraviroc
Description: Treatment change
Study NCT04832633 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Different contrast media injection methods
Description: Different contrast media injection methods
Study NCT02408523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasosamide Oral Solution
Description: * Active Substance: Lacosamide~* Pharmaceutical Form: Oral Solution~* Concentration: 10 mg/ml~* Route of Administration: Oral use
Study NCT02408523 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: * Active Substance: Placebo~* Pharmaceutical Form: Film-coated Tablet~* Concentration: 50 mg~* Route of Administration: Oral use
Study NCT03161184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SUSTAIN Smartphone training of CHW (SP+)
Description: Intervention (Smart phone assisted): During prenatal household visits, the smart phone based application guides CHW through electronic decision tree protocols, directing them to specific health/nutrition counseling topics and messages based on each woman's gestational age, and her answers to a specific series of diagnostic questions. Based on the client's gestational age, the tool directs CHW to lessons in an accompanying photo book, and reminds them to counsel on the importance of accessing timed and targeted maternal health services at health facilities. The application also assists CHW to identify danger signs during pregnancy, flags clients who require immediate referral to health facilities, and reminds CHW to follow-up with clients who were previously referred to clinics.
Study NCT02408523 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Solution
Description: * Active Substance: Placebo~* Pharmaceutical Form: Oral Solution~* Concentration: 10 mg/ml~* Route of Administration: Oral use
Study NCT03137628 — intervention group
Intervention type: OTHER
Intervention: colectomy, GA and MV
Description: general anesthesia protocol: anesthesia induction (midazolam 0.1mg/kg, sufentanil 0.5ug/kg, etomidate 0.3mg/kg, cisatracurium 0.2mg/kg); anesthesia maintenance \[sevoflurane 1.5-3%, cisatracurium 0.1mg/kg/h, sufentanil is supplemented during the entire surgical procedure according to patients' anesthetic situation, dexmedetomidine（used conditionally）0.4ug/kg/h\].~mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
Study NCT00480389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Starting dose: 400 mg (2x200mg tablets) BID (total= 800mg/day) taken orally. The dose can be adjusted as per investigator if required due to toxicity (ex. 200mg BID, 200mg QD). Study drug is taken for 12 weeks preoperatively. Patients restart on study drug 6 weeks postoperatively and continue until progression or unacceptable toxicity occurs.
Study NCT03161184 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SUSTAIN Paperbased training of CHW (SOC)
Description: SUSTAIN Paperbased training of CHW (SOC): During prenatal household visits, the CHW asks a specific series of diagnostic questions based on the client's gestational age, offers counsel on the importance of accessing appropriate maternal health services at health facilities and uses lessons in an accompanying photo book to deliver messages on a variety of maternal and newborn health and nutrition topics. CHW are trained to identify danger signs during pregnancy, flag clients who require immediate referral to health facilities, and follow-up with clients who were previously referred to clinics.
Study NCT02888730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin nebulized nasally
Description: Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of tobramycin twice a dayAmpoules of tobramycin are filled by 5 ml containing 300 mg of tobramycin and 11.25 mg of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete.Antibiotic retained for the study, tobramycin is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. The study's product will be prepared with Base Tobramycin and excipients in accordance with TOBI's composition.
Study NCT02888730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic serum nebulized nasally
Description: Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of placebo (Nacl 0.9%) twice a day.Ampoules of placebo are filled by 5 ml containing of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete. Placebo for the study is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. Patients in placebo arm will receive 5ml of sodium chloride with the same color (light yellow transparent) as tobramycin
Study NCT03140787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Spray of Lidocaine HCL
Description: This spray consists of lidocaine hydrochloride-epinephrine hydrochloride
Study NCT03161184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SUSTAIN Paperbased training of CHW (SOC)
Description: SUSTAIN Paperbased training of CHW (SOC): During prenatal household visits, the CHW asks a specific series of diagnostic questions based on the client's gestational age, offers counsel on the importance of accessing appropriate maternal health services at health facilities and uses lessons in an accompanying photo book to deliver messages on a variety of maternal and newborn health and nutrition topics. CHW are trained to identify danger signs during pregnancy, flag clients who require immediate referral to health facilities, and follow-up with clients who were previously referred to clinics.
Study NCT03935945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention
Description: Participants in the intervention group will receive a computerized personalized feedback intervention (PFI) lasting approximately 20-30 minutes. PFI highlights discrepancies between one's own drinking and typical drinking; reframes use in terms of personal, social, financial, and health consequences; and, offers strategies for reducing alcohol use. The feedback is non-confrontational in tone, seeks to increase motivation to reduce drinking and is based on the information provided during the baseline assessment
Study NCT01659437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin Extended Release
Description: oral administration of Clarithromycin extended release
Study NCT01659437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Streptomycin intramuscular injection
Description: daily intramuscular drug injection
Study NCT00781612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered as per local prescribing information.
Study NCT00781612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered as per local prescribing information.
Study NCT00781612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab will be administered intravenously at a dose of 420 milligrams (mg) no more frequently than every 3 weeks (Q3W) (or as directed in the parent study protocol if less than Q3W).
Study NCT00781612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered as per local prescribing information.
Study NCT00781612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine will be administered as intravenous (IV) infusion. Participants on weekly dosing schedule of trastuzumab emtansine in parent study, may switch to Q3W schedule as per the clinical judgment of the investigator. The starting dose of Q3W schedule must not exceed 3.6 milligrams per kilograms (mg/kg).
Study NCT00781612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg by IV infusion every three weeks (Q3W)
Study NCT03140787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration injection of Lidocaine HCL
Description: This is the ordinary method of establishing anesthesia for patients undergoing dental treatment for caries.
Study NCT03878212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth application with interactivity
Description: a mHealth device with interactivity with nurse case manager
Study NCT03878212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mHealth application
Description: a mHealth device
Study NCT02995863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rigid Rocker Sole Footwear
Study NCT02995863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Footwear
Study NCT02146352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AXIOS Stent with Electrocautery Enhanced Delivery System
Description: Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.
Study NCT03660566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test - Implant with L-PRF
Description: The patient's blood will be collected and the tubes (4) will be inserted into a tabletop centrifuge (Kasvi). Using a 2500rpm for 12 minutes protocol, the leucocyte- and platelet-rich fibrin clot will be prepared using a kit consisting of a perforated metal box where the clots will be positioned and covered by a metal plaque. The pressure exerted on the clot will lead to the formation of L-PRF membranes, which will be used to cover the ridge after placement of the implant. Then, the flap will be sutured.
Study NCT03660566 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control - Implant without L-PRF
Description: Single implant installation surgery in maxillary esthetic area.
Study NCT00935766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: Subjects meeting eligibility criteria will be randomized to receive a supply of omega-3-acid ethyl esters or placebo, and instructed to take 4 capsules daily. A 3-month supply of study drug will be given following randomization and at 3, 6, and 9 months. Subjects will be asked to bring unused supplies to each quarterly visit for ascertainment of adherence.
Study NCT00935766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04126876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilsotolimod
Description: Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
Study NCT02252965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin IR
Description: Subjects will receive Metformin Immediate Release (IR) tablets, orally once daily at a dose of 500 milligram (mg) for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
Study NCT02252965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Subjects will receive Metformin Extended Release (XR) tablets, orally once daily at a dose of 500 mg for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
Study NCT01705093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flavonoid-rich freeze-dried strawberry powder
Description: 50g of flavonoid-rich freeze-dried strawberry powder
Study NCT01705093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: macronutrient-matched control powder
Description: 50g macronutrient-matched powder that will lack strawberry flavonoids
Study NCT02124304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neck exercises using both manual and Thera-Band elasatic resistance
Description: Exercises will include cervical flexion and extension, and cervical right and left side-bending, and rotation. All 6 exercises will be done with both manual and elastic (Thera-Band) resistance.Manual Resistance is applied by the subject placing their own hand on their head and pushing in to it. Thera-Band bands will be used to provide elastic resistance
Study NCT04126876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (0.9% sodium chloride)
Description: Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
Study NCT01066624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Sodium Chloride irrigation solution
Description: Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study
Study NCT01066624 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy (ice chips)
Description: Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion.
Study NCT01606774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modernized prenatal care
Description: Home monitoring/phone surveillance/28 week ultrasound in place of 4-5 routine prenatal visits between 18 and 36 weeks
Study NCT02114255 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of 0.9% NaCl.
Study NCT02114255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: Vaccination with the live attenuated BCG vaccine.
Study NCT00680797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Testosterone gel
Study NCT00680797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen
Description: Estrogen patch
Study NCT03300921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Product: Paricalcitol~Dose/Route/Regimen:~Arm A: 50mcg IV weekly Arm B: 12mcg PO daily
Study NCT03341832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1203
Description: oral dose for 7 days
Study NCT03341832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-1203-R
Description: oral dose for 7 days
Study NCT03341832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-1203 placebo
Description: oral dose for 7 days
Study NCT03341832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NVP-1203 placebo
Description: oral dose for 7 days
Study NCT03341832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1203-R placebo
Description: oral dose for 7 days
Study NCT03341832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NVP-1203-R placebo
Description: oral dose for 7 days
Study NCT02071355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 100 mg
Description: Participants will receive TMC435 100 mg capsule once daily from Day 1 to Day 7 after food.
Study NCT02071355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 150 mg
Description: Participants will receive TMC435 150 mg capsule once daily from Day 1 to Day 7 after food.
Study NCT02635828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.075 mg IV
Description: At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.
Study NCT02635828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg IV
Description: At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.
Study NCT02635828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg IV
Description: At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.
Study NCT03767920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: TAP block with 20 ml of 0.25% bupivacaine bilaterally
Study NCT03767920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: TAP block with 4 mg dexamethasone bilaterally
Study NCT03767920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to dexamethasone
Description: TAP block with 4 mg placebo to dexamethasone bilaterally
Study NCT00854035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0431/ONO-5435
Description: Double-blind period (16 wk); 50 mg QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50mg QD to 100mg QD
Study NCT04991181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg BIA 5-1058
Description: Capsules, oral administered to subjects between 08:00 and 09:00 hours in the morning of Day 1after an overnight fast of at least 10 hours. The study drug was swallowed together with 240 mL tap water (room temperature).
Study NCT00854035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-0431/ONO-5435
Description: Double-blind period (16 wk); placebo QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
Study NCT01483911 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0171
Description: Single or multiple ascending doses (2.1-210 mg), administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
Study NCT01483911 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or multiple doses, administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
Study NCT02434731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy® device
Description: Buzzy® is a battery-powered device for venipuncture pain relief combining cold, vibration, and distraction.
Study NCT00312494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with mood stabilizer (either lithium or divalproex)